BlackRock Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

BlackRock Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$8K	Hold	558	–	–	﹤0.01%	3590
2016 Q3	$7K	Sell	558 -1	-0.2%	-$10	﹤0.01%	3615
2016 Q2	$5K	Sell	559 -633	-53%	-$7.59K	﹤0.01%	3658
2016 Q1	$10K	Hold	1,192	–	–	﹤0.01%	3572
2015 Q4	$15K	Sell	1,192 -553	-32%	-$15.2K	﹤0.01%	3559
2015 Q3	$106K	Sell	1,745 -13	-0.7%	-$938	﹤0.01%	3071
2015 Q2	$137K	Buy	1,758 +420	+31%	+$35.2K	﹤0.01%	3028
2015 Q1	$91K	Buy	1,338 +190	+17%	+$16.3K	﹤0.01%	3083
2014 Q4	$106K	Sell	1,148 -55	-5%	-$5.69K	﹤0.01%	3011
2014 Q3	$127K	Buy	1,203 +37	+3%	+$5.15K	﹤0.01%	2876
2014 Q2	$167K	Buy	1,166 +19	+2%	+$2.78K	﹤0.01%	2743
2014 Q1	$173K	Buy	1,147 +114	+11%	+$22.5K	﹤0.01%	2734
2013 Q4	$189K	Buy	1,033 +271	+36%	+$49.6K	﹤0.01%	2682
2013 Q3	$168K	Buy	762 +20	+3%	+$4.25K	﹤0.01%	2660
2013 Q2	$130K	Buy	+742	New	+$193K	﹤0.01%	2723

Other funds holding MDGL

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

BlackRock Advisors's MDGL Position: Q4 2016 in Review

BlackRock Advisors held its Madrigal Pharmaceuticals (MDGL) position steady in Q4 2016 at 558 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #3590.

BlackRock Advisors first reported a position in MDGL in Q2 2013 and has held it in 15 quarters since. The position peaked at $189K in Q4 2013. 31 funds tracked by Wall St. Rank hold MDGL as of Q4 2016.

BlackRock Advisors held 558 shares of Madrigal Pharmaceuticals worth $8K as of Q4 2016.
BlackRock Advisors left its Madrigal Pharmaceuticals share count unchanged in Q4 2016.
Madrigal Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3590 holding.
BlackRock Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Madrigal Pharmaceuticals position peaked at $189K in Q4 2013.
31 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.